LWANC
ESPR

Laurel Wealth Advisors (North Carolina)’s Esperion Therapeutics ESPR Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,500
Closed -$9.25K – 332
2025
Q4 		$9.25K Buy
+2,500
New +$8.08K ﹤0.01% 493
2025
Q2 		– Sell
-2,500
Closed -$3.6K – 336
2025
Q1 		$3.6K Hold
2,500
– – ﹤0.01% 565
2024
Q4 		$5.5K Hold
2,500
– – ﹤0.01% 542
2024
Q3 		$4.13K Hold
2,500
– – ﹤0.01% 535
2024
Q2 		$5.55K Hold
2,500
– – ﹤0.01% 472
2024
Q1 		$6.7K Hold
2,500
– – ﹤0.01% 466
2023
Q4 		$7.47K Hold
2,500
– – ﹤0.01% 423
2023
Q3 		$2.45K Hold
2,500
– – ﹤0.01% 502
2023
Q2 		$3.48K Hold
2,500
– – ﹤0.01% 486
2023
Q1 		$3.98K Hold
2,500
– – ﹤0.01% 474
2022
Q4 		$15.6K Hold
2,500
– – ﹤0.01% 352
2022
Q3 		$17K Hold
2,500
– – ﹤0.01% 346
2022
Q2 		$16K Hold
2,500
– – ﹤0.01% 348
2022
Q1 		$12K Hold
2,500
– – ﹤0.01% 392
2021
Q4 		$13K Hold
2,500
– – ﹤0.01% 385
2021
Q3 		$30K Hold
2,500
– – 0.01% 305
2021
Q2 		$53K Hold
2,500
– – 0.01% 274
2021
Q1 		$70K Hold
2,500
– – 0.02% 236
2020
Q4 		$65K Sell
2,500
-240
-9% -$7.19K 0.02% 236
2020
Q3 		$102K Buy
2,740
+2,500
+1,042% +$99K 0.03% 178
2020
Q2 		$12K Hold
240
– – ﹤0.01% 359
2020
Q1 		$8K Hold
240
– – ﹤0.01% 380
2019
Q4 		$14K Hold
240
– – ﹤0.01% 355
2019
Q3 		$9K Hold
240
– – ﹤0.01% 390
2019
Q2 		$11K Hold
240
– – ﹤0.01% 364
2019
Q1 		$10K Hold
240
– – ﹤0.01% 368
2018
Q4 		$11K Buy
+240
New +$11.6K ﹤0.01% 340

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s ESPR Position: Q1 2026 in Review

Laurel Wealth Advisors (North Carolina) sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 2,500 shares — an estimated $9.25K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in ESPR in Q4 2018 and held it in 27 quarters. The position peaked at $102K in Q3 2020. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 2,500 Esperion Therapeutics shares in Q1 2026, an estimated $9.25K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Esperion Therapeutics in Q4 2018 and held it in 27 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Esperion Therapeutics position peaked at $102K in Q3 2020.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 13 May 2026.